Another Gene-Editing IPO

Intellia Therapeutics, which seeks to develop CRISPR-based technologies to target rare diseases, is hoping to raise $120 million in an initial public offering.

Bob Grant
Bob Grant

Bob Grant is Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.

View full profile.

Learn about our editorial policies.

WIKIMEDIA, ERNESTO DEL AGUILA III, NHGRIEditas Medicine made headlines earlier this year when it snagged more than $94 million in its initial public offering (IPO), selling 5.9 million shares at $16 apiece. Now, another CRISPR-focused firm, Intellia Therapeutics, is throwing its hat into the IPO ring. Intellia, which is based in Cambridge, Massachusetts, filed the paperwork required to go public yesterday (April 11). According to The Boston Globe, Intellia is seeking to raise about $120 million with its IPO, but the details of how many shares it will offer and at what price have not yet been announced.

The juxtaposition of Intellia’s IPO and that of Editas is made all the more intriguing because the companies were founded by CRISPR-Cas9 pioneers who remain locked in a patent dispute over the technology. Intellia was spun out of Caribou Biosciences, which was founded by University of California, Berkeley researcher Jennifer...

Meanwhile, Intellia yesterday (April 11) announced a $75 million licensing deal with Regeneron Pharmaceuticals. Regeneron is paying the hefty sum so that it can develop new CRISPR-based therapies that target genes expressed in the liver.

“We are excited to be partnering with Regeneron, an industry leader in human genetics research,” Nessan Bermingham, Intellia CEO and cofounder, said in a statement. “Regeneron’s focus on advancing science to medicine is an excellent fit with Intellia’s approach, and together, we aim to bring potential cures to patients who are suffering from life-threatening rare diseases and genetic diseases.”

Update (May 6): Intellia has sold 6 million shares at $18 a pop to rake in $108 million in its IPO. The CRISPR-using drugmaker's stock debuted on the Nasdaq today under the ticker NLTA.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?